Business Wire

Lineage Unveils the Global Food Chain Innovation Challenge to Combat Food Waste

3.7.2024 10:00:00 EEST | Business Wire | Press release

Share

Lineage, the world’s largest global temperature-controlled warehouse REIT, today announced the launch of its pioneering initiative, the Food Chain Innovation Challenge. This aspiring global competition invites students and startups to develop and pitch groundbreaking solutions aimed at tackling one of the world’s most pressing issues: food waste, particularly postharvest losses.

The challenge will convene bright minds at three major events across the globe: London, United Kingdom on November 14; Amsterdam, The Netherlands on November 19; and San Francisco, United States also on November 19. Participants are called to present their innovative solutions that can empower different regions of the world – from mature to emerging and developing markets – to mitigate postharvest food spoilage through affordable and scalable methods, thereby enhancing food security, quality, safety, and market access.

Winners from each regional event will win a cash prize. Additionally, an overall winner will be selected from the regional winners and announced in December. The grand prize winner will receive entry into an incubator program tailored to help them further refine their business development skills and scale their solution effectively.

At the events, participants will be asked to pitch their ideas to a panel of esteemed judges, concentrating their efforts in one of four specific areas:

  • Reducing food waste: Introduce technologies and strategies to diminish food loss from farm to market.
  • Innovative food preservation techniques: Propose novel methods that enhance food longevity and reduce spoilage.
  • Access to nutritious food: Improve the logistics of food distribution to enhance the availability of nutritious foods in underserved areas.
  • Data-driven insights and analytics: Employ analytics and IoT to optimize supply chains and reduce waste.

“According to the UN Environment Programme’s Food Waste Index Report 2024, the latest data from 2022, shows 1.05 billion tonnes of food went to waste — an amount sufficient to nourish billions. This reality is stark, especially considering that over 783 million individuals globally suffer from undernourishment. By reducing food waste, we can significantly enhance global food security and address hunger,” said Greg Lehmkuhl, President and CEO of Lineage, “At Lineage, we are dedicated to spearheading innovation across the global food supply chain. Through our Food Chain Innovation Challenge, we are seeking to cultivate solutions that not only tackle food waste but also advance sustainable development. We are eager to witness the emergence of these new ideas and their evolution into practical, impactful strategies.”

The Food Chain Innovation Challenge underscores Lineage's commitment to sustainability, improving the global management of food storage, transport, and distribution. If you're interested in participating, apply here. For a glimpse into the 2023 Hackathon, the predecessor to The Food Chain Innovation Challenge, held in Amsterdam watch this video. Also, hear insights from last year's winner to get inspired and understand the impact of winning this prestigious challenge.

About Lineage

Lineage, Inc. is the world’s largest global temperature-controlled warehouse REIT with a network of over 480 strategically located facilities totaling over 84.1 million square feet and 3.0 billion cubic feet of capacity across countries in North America, Europe, and Asia-Pacific. Coupling end-to-end supply chain solutions and technology, Lineage partners with some of the world’s largest food and beverage companies to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world. (onelineage.com)

View source version on businesswire.com: https://www.businesswire.com/news/home/20240703425894/en/

Contacts

Nina Bosch
+31 6 81938713
nbosch@onelineage.com

Christina Wiese
734-608-1855
cwiese@onelineage.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye